Marc TessierLavigne - Regeneron Pharmaceuticals Independent Director

REGN -- USA Stock  

Quarterly Earning Report: November 5, 2019  

  Director
Dr. Marc TessierLavigne, Ph.D., is Independent Director of the Company. He was the President of Stanford University since September 2016. Before assuming his role at Stanford, he served as the President of The Rockefeller University and a Carson Family Professor and head of the Laboratory of Brain Development at The Rockefeller University from March 2011. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford University from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001. Dr. TessierLavigne is a member of the National Academy of Sciences, the National Academy of Medicine, and a fellow of the Royal Societies of London and Canada. Dr. TessierLavigne is a member of the Board of Directors of Denali Therapeutics Inc., and previously served on the board of directors of Pfizer Inc., Agios Pharmaceuticals, Inc., and Juno Therapeutics, Inc.
Age: 58  Director Since 2011  Ph.D    
914 847 7000  http://www.regeneron.com
TessierLavigne distinguished scientific and academic background, and his significant industry experience, including experience in senior scientific leadership roles at a leading biopharmaceutical company, led the board to conclude that Dr. TessierLavigne should serve as a director.

Marc TessierLavigne Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3 M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

William SteereZoetis
2013
Sridar IyengarDr Reddys Laboratories Ltd
2011
Geoffery MerszeiOrigin Agritech Limited
2016
Willie ReedZoetis
2014
Robert ScullyZoetis
2013
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
William YoungVertex Pharmaceuticals Incorpor
2014
Bruce CarterDr Reddys Laboratories Ltd
2008
Michael JandernoaPerrigo Company Plc
2007
Donal OConnorPerrigo Company Plc
2014
Gregory NordenZoetis
2013
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Geoffrey ParkerPerrigo Company Plc
2016
Sanjay KhoslaZoetis
2013
Larry CordellOrigin Agritech Limited
2012
Shikha SharmaDr Reddys Laboratories Ltd
2019
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Frank DAmelioZoetis
2016
Bharat DoshiDr Reddys Laboratories Ltd
2016
Ravi BhoothalingamDr Reddys Laboratories Ltd
2000
Fei WangOrigin Agritech Limited
2019

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Current Sentiment - REGN

Regeneron Pharmaceuticals Investor Sentiment

Majority of Macroaxis users are at this time bullish on Regeneron Pharmaceuticals. What is your perspective on investing in Regeneron Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

VMW   
Purchased a lot of shares of
a day ago
Traded for 152.08
SECI   
Purchased over 70 shares of
a day ago
Traded for 35.0
V   
Purchased few shares of
a day ago
Traded for 177.94
C   
Purchased over 40 shares of
a day ago
Traded for 69.6
FB   
Purchased few shares of
a day ago
Traded for 190.39
Additionally take a look at Your Equity Center. Please also try Cryptocurrency Correlation module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins and exchanges.
Search macroaxis.com